Blue Chip Patient Recruitment, a division of Blue Chip Marketing Worldwide, a full-service integrated marketing agency, has successfully partnered with Orexigen Therapeutics to accelerate patient enrollment of The Light Study, Orexigen's cardiovascular outcomes trial evaluating Contrave (naltrexone sustained release (SR)/bupropion SR).
URL: http://www.news-medical.net/news/20121221/BCPR-Orexigen-partner-to-accelerate-patient-enrollment-for-Contrave-obesity-Light-Study.aspx
No comments:
Post a Comment